Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman
U.S. STOCKS ON THE MOVE-Zscaler, Carlyle, Weight Watchers
Annovis Bio tumbles on share offering
Brief: Annovis Announces $10 Million Underwritten Offering Of Common Stock And Accompanying Warrants
Brief: Annovis Secures U.S. Patent For Buntanetap In The Prevention And Treatment Of Neurological Injuries Caused By Brain Infections
Brief: Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial
Brief: Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results
Brief: Annovis Secures Dsmb Approval To Advance Pivotal Phase 3 Trial Of Buntanetap In Alzheimer’S Disease
Brief: Annovis Announces Open-Label Extension Study For Parkinson's Disease Patients
Analysis: Alzheimer's drug hunt learns from cancer fight's multi-target playbook
Brief: Annovis Announces FDA Meeting To Discuss Parkinson's Disease Dementia Program Reaffirms FDA Alignment On Pivotal Phase 3 Alzheimer's Disease Study
Pathology To Accelerated Cognitive Decline In Parkinson's Patients
Brief: Annovis Announces $3.4 Million Registered Direct Offering Of Common Stock Priced At-The-Market Under The NYSE Rules
Brief: Annovis announces closing of $6 million offering of common stock
Brief: Annovis Announces $6 Million Registered Direct Offering Of Common Stock
Brief: Annovis Announces Novel Biomarker Data In Alzheimer’S Patients Supporting Buntanetap’S Potential As A Disease-Modifying Treatment